Lentinan could exhibit significant
biological activity favorable for human health and disease control such as the recovery of patients with
liver cancer. In order to investigate the effect of
lentinan dose dependence between immunoprophylaxis and promotion of
cancer cell proliferation of the murine
liver cancer, different concentrations of
lentinan were prepared for the test in vitro (MTT assay) and in vivo (cumulative survival assay, spleen lymphocyte proliferation tests and peritoneal macrophage phagocytosis assays). New emerging
proteins of the H22 cell incubated with
lentinan was demonstrated by MS analysis and protein database searching.
Lentinan was non-toxic for HL7702 cells but inhibited H22 cells proliferation obviously in a dose-dependent manner. In vivo, the proliferation of H22 hepatocarcinoma cells was inhibited by
lentinan 0.4mg/kg
body weight (L2, survival rate, 20%, PPP<0.01). Six
proteins 60Sacidic
ribosomal protein P2, Peroxiredoxin-2,
Annexin A5, PDZ and LIM domain protein 1, Src substrate
cortactin and
Moesin were found as emerging
proteins of the H22 cell incubated with high dose
lentinan which related to
cancer promotion closely. In conclusion, Thelentinan was relatively safe and could inhibit the proliferation of H22
cancer cells through immunity improvement when it's intake was in proper quantity.